课题基金 / 基金详情

Anticancer therapy by hybrids of dendritic cells and interferon-α-overexpressing cells

Anticancer therapy by hybrids of dendritic cells and interferon-α-overexpressing cells
树突状细胞和干扰素-α-过表达细胞的杂交抗癌治疗
批准号:
14570509
负责人:
HIROISHI Kazumasa
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004

项目摘要

项目成果

HIROISHI Kazumasa的其他基金

相似基金

相关文献

中文摘要
翻译
以树突状细胞(DC)为基础的免疫治疗已被用于临床治疗癌症,尽管大多数尝试都没有得到足够的反应。树突状细胞与肿瘤细胞的融合技术已经被开发出来,并在实验模型和临床试验中得到广泛应用。为了克服肿瘤患者的免疫抑制状态,基于肿瘤的疫苗接种结合细胞因子基因治疗也被用于治疗这些肿瘤。我们先前展示了干扰素-α过表达肿瘤在免疫原性低的小鼠结直肠癌模型中的效果。因此,我们认为,与DC和野生型细胞的杂交治疗相比,DC和干扰素-α高表达肿瘤细胞的杂交瘤免疫治疗可能具有更好的抗肿瘤作用。在这项研究中,我们评估了树突状细胞和干扰素-α基因转导的结直肠癌细胞杂交体在小鼠模型中的抗肿瘤作用。我们建立了一株高表达干扰素α的结直肠癌细胞系(mC38-干扰素α,产量为157.0…更多+-4.2ng干扰素-α/10^6细胞/48小时)。我们将DC和mC38-干扰素α细胞与聚乙二醇制得杂交瘤细胞。为评价其预防效果,在注射野生型MC38(MC38-WT)前7天将杂交瘤细胞接种于免疫活性小鼠体内。作为对已建立的肿瘤的治疗,在MC38-WT细胞注射后7天,对应接种杂交瘤。杂交瘤细胞中有17%~25%的DC与Mc38-干扰素α融合细胞产生大量干扰素-α。预先注射杂交体有效地防止了所有小鼠的野生型肿瘤的种植。在对已建立的肿瘤的治疗模型中,DC和MC38-干扰素α细胞的杂交比DC和MC38-WT细胞的杂交更有效地抑制肿瘤的生长。免疫组织化学分析显示,DC和Mc38-干扰素α细胞的杂交瘤组织中有明显的CD8~+细胞浸润。用树突状细胞和干扰素-α转导的肿瘤细胞杂交瘤细胞进行免疫治疗能有效地诱导细胞抗肿瘤免疫反应,值得在临床试验中考虑。较少
英文摘要
Dendritic cell (DC)-based immunotherapy has been used clinically against cancer although most attempts showed insufficient responses. Fusion technique for DCs and tumor cells has been developed and widely used in experimental models as well as clinical trials. To overcome an immunosuppressed state in patients with tumors, tumor-based vaccination in combination with cytokine gene therapy has also been used in treatment of these tumors. We previously showed the efficacy of IFN-α-overexpressing tumor in a murine poorly immunogenic colorectal cancer model. Therefore, we thought that immunotherapy using hybrids of DCs and IFN-α-overexpressing tumor cells might have more antitumor effects compared with therapy with hybrids of DCs and wild-type cells. In this study, we evaluated antitumor effects of therapy with hybrids of DCs and IFN-α gene transduced colorectal cancer cells in a murine model. We established an IFN-α-overexpressing MC38 colorectal cancer cell line (MC38-IFNα, producing 157.0 … More +-4.2 ng of IFN-α/10^6cells/48h) using a retroviral vector. We made hybrids of DCs and MC38-IFNα cells with polyethyleneglycol. To evaluate the preventive effects, the hybrids were injected in immunocompetent mice 7 days before injection of wild-type MC38 (MC38-WT). As a therapy against established tumors, hybrids were inoculated contralaterally 7 days after MC38-WT cells had been injected. Hybrids were detected 17-25% of the fused DCs and MC38-IFNα cells, and these cells produced a large amount of IFN-α. Preinjection of hybrids prevented implantation of wild-type tumors effectively in all mice. In the therapeutic model against established tumors, hybrids of DCs and MC38-IFNα cells suppressed growth of the tumors more effectively than hybrids of DCs and MC38-WT cells. Immunohistochemical analysis showed marked infiltration of CD8^+ cells in the established tumors of mice treated with hybrids of DCs and MC38-IFNα cells. Immunotherapy using hybrids of DCs and IFN-α-transduced tumor cells induces cellular antitumor immune response effectively, and should be considered in clinical trials. Less
期刊论文(26)
专著(0)
科研奖励(0)
会议论文
Interferon-alpha and interleukin-12 gene therapy of cancer : interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing
干扰素-α和白介素-12对癌症的基因治疗:干扰素-α诱导肿瘤特异性免疫反应,而白介素-12刺激非特异性杀伤
DOI: --
发表时间: 2003
期刊: Cancer Immunology and Immunotherapy 52
影响因子: --
作者: [Junichi Eguchi, et al.]
通讯作者: et al.
Jun-ichi Eguchi: "Interferon-α and Interleukin-12 Gene Therapy for Cancer, Interferon-α Induces Tumor specific Immune Responses While Interleukin-12 Stimulates Non-specific Killing"Cancer Immunology and Immunotherapy. (In press). (2003)
Jun-ichi Eguchi:“干扰素-α 和白细胞介素 12 基因治疗癌症,干扰素-α 诱导肿瘤特异性免疫反应,而白细胞介素 12 刺激非特异性杀伤”癌症免疫学和免疫治疗(2003 年)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
DOI: 10.1038/sj.gt.3302401
发表时间: 2005-05-01
期刊: GENE THERAPY
影响因子: 5.1
作者: [Eguchi, J, Hiroishi, K, Imawari, M]
通讯作者: Imawari, M
DOI: 10.1097/00002371-200205000-00005
发表时间: 2002-05-01
期刊: JOURNAL OF IMMUNOTHERAPY
影响因子: 3.9
作者: [Shimamura, H, Cumberland, R, Baar, J]
通讯作者: Baar, J
共 10 条
    Interferon-producing killer dendritic cell-based immunotherapy for gastrointestinal cancer
    • 批准号:
      19590738
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      HIROISHI Kazumasa
    • 依托单位:
    海外基金